Phase two clinical trial of limited stage lymphoblastic lymphoma.
Phase 2
Completed
- Conditions
- imited stage lymphoblastic lymphoma
- Registration Number
- JPRN-jRCTs041180131
- Lead Sponsor
- Sekimizu Masahiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Newly diagnosed patients with limited T and B cell lymphoblastic lymphoma
Exclusion Criteria
1, Down's syndrome
2, previous malignancy of any type
3, Prior stem cell or organ transplantation
4, Congenital or acquired immunodeficiency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3 year event-free survival
- Secondary Outcome Measures
Name Time Method (1) 3year overall survival<br>(2)Incidence of therapy-rerated severe toxicity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms are being targeted in the JPRN-jRCTs041180131 phase II trial for limited stage lymphoblastic lymphoma?
How does the JPRN-jRCTs041180131 trial compare to standard-of-care treatments for lymphoblastic lymphoma in terms of efficacy and survival outcomes?
What biomarkers are used for patient selection and response prediction in the LLB-NHL03 phase II lymphoblastic lymphoma trial?
What are the known or potential adverse events associated with the JPRN-jRCTs041180131 trial and how are they managed in clinical practice?
What combination therapies or related compounds are being explored alongside the JPRN-jRCTs041180131 trial for lymphoblastic lymphoma treatment?